Upload
ritika-khurana
View
421
Download
5
Tags:
Embed Size (px)
Citation preview
MANAGEMENT OF APLASTIC ANEMIA
Presentor – Dr. Ritika KhuranaModerator – Dr. Sunil Gomber
APLASTIC ANEMIA
One of the types of bone marrow failure syndromes presenting with reduced hematopoeitic cells of all 3 lineages
BM failure syndromes Single cytopenia1. RBC’sDiamond blackfann syndromeCongenital dyserythropoetic anemiaPearson syndromeTransient erythroblastopeniaChronic parvovirus B19 infection2. WBC’sShwachman diamond syndromeKostmann’s syndromeReticular dysgenesis3. PLATELETSCongenital amegakaryocytic thrombocytopeniaThrombocytopenia absent radii syndrome Generalized BM failure
Classification
Inherited - 30%Acquired - 70%
InheritedFanconi’s Anemia – MCDyskeratosis congenitaShwachman diamond syndromeAmegakaryocytic ThrombocytopeniaDiamond blackfann syndromeFamilial Aplastic AnemiasNon-hematolog syndromes Down’s Dubowitz Seckel syndrome
Acquired Idiopathic – MC
Secondary• Radiation• Drugs & chemicals• Infections – EBV, Hep virus, HIV, CMV• Immune diseases - Eosinophilic
fascitis, hypoimmunoglobinemia, SLE• Thymoma• GVHD• PNH• Myelodysplasia
Camitta’s ClassificationMild/Mod(hypoplastic anemia) ANC 500-1500 Platelet count - 20k-1lacSevere aplastic anemia* ANC < 500 Platelet count - <20kVery severe* ANC < 200
*in addition <25% bone marrow cellularity
Pathogenesis
Overproduction of cytokines
progenitor cells shortened telomeresImmune susceptibilityPoor microenvironment (seed and soil theory)
Clinical EvaluationHistory Recent illnesses Medications Exposure to toxins/ Radiation Family h/o bleeding disorders,
malignancies, congenital anomaliesO/E Vitals Ht & Wt Congenital anomalies
InvestigationsCBC, DLCReticulocyte countBM aspiration n biopsySkeletal surveyOthers – LFT, serologic test, flow
cytometry, DEB/ Mitomycin test(chromosome breakage analysis), comet assay, Autoimmune disease evaluation
MANAGEMENT
SUPPORTIVE
DEFINITIVETransfusio
nsTreatment of infections
Bone Marrow TransplantationImmunosupp- ressive Therapy Others 1) Alemtuzumab 2) Hematopoietic
GF’s3) Androgens4) Corticosteroids5) Anti IL2 –
Daclizumab, Eculizumab
TransfusionsPlatelet transfusion if <10000 or Visceral bleedingPlateletpheresis(Single donor platelets)
to be preferredAvoid transfusion from related donor
Role of antibioticsNo role of prophylactic antibioticsFever or documented infection with
severe neutropenia <500
Immunosuppressive therapy
ATG/ALG
Cyclosporine
Combined IST
ATG- antithymocyte globulin
2 types – horse and rabbit ATGImmunization of both by
human thoracic duct lymphocytes or thymocytes
Mechanism – act against T- lymphocytes, downregulating production of IFN gamma, IL2
PrerequisitesSkin testing to be done for
hypersensitivityDouble lumen central catheter Platelet count to be maintained
above 20kDrugs like ß-blockers to be
avoidedAvoid starting on weekends or
late during day
How to administer?DOSE –40mg/kg over 4hrs daily
for 4daysPrednisone 1 mg/kg started on
day1, continued for 2 weeks (prophylaxis for serum sickness)
Premedications – diphenhydramine, acetaminophen
Hydration n supplemental oxygen
Side effects n managementSerum sickness- steroidsRash, fever- diphenhydramine,
acetaminophenRigors- mepiridineInc transaminases – regular
monitoring
Monitoring responseResponse – within first 3 monthsEarliest response – appearance of
granulocytes and nucleated RBC’s
Order of rise – 1. RBC’s ( inc HbF)2. WBC’s3. Platelets
Horse vs Rabbit ATGRabbit ATG more lymphocytotoxicHematologic response to rabbit ATG
(37%) about half that observed with standard horse ATG (68%),
Inferior survival noted in the rabbit ATG arm
Scheinberg P,et al. Horse versus rabbit antithymocyte globulin in acquired aplastic
anemia. N Engl J Med 2011;365(5):430-438.
Cyclosporine Fungal cyclic undecapeptideInhibits T-cell - IL-2, IFN-gammaCyclosporine alone lower response rates n
higher risk of disease progressionBest results seen as combined IST(with
ATG)5yr survival rate- 70%
Rosenfeld SJ, et al.Intensive immunosuppression with antithymocyte globulin and cyclosporine as
treatment for severe acquired aplastic anemia. Blood 1995;85(11):3058-3065
How to administer?Twice daily to maintain trough levels 100-
250ng/mlStarting dose 15mg/kg/dayResponse takes weeks to monthsMinimum trial period should be 3-6mthsIdeally ATG×4days n cyclosporine×6-
12mthsCyclosporine should be gradually tapered
Scheinberg P, Horse versus rabbit antithymocyte globulin
in acquired aplastic anemia. N Engl J Med 2011;365(5):430-438
Adverse effects n managementHypertension – amlodipineHirsutism Gingival hyperplasia – azithromycinInc creatinine levels – monitoring and
adjusting dose if creat > 2mg/ml – temp cessation n
reintroduction at lower dosesP.carinii pneumonia- monthly
aerosolized pentamidineDev of Clonal hematopoeitic disorders
Definitions Complete response- transfusion
independence, neutrophil count >1500/L, platelet count>1lac n Hb>10g/dl
Partial remission- transfusion independence, Hb by atleast 2g/dl n actual value>8, granulocytes by atleast 500/L, platelets>30k
No response- continued severe aplastic anemia
Refractory SAA – severe pancytopenia 6mths after initiation of IST
Chandra J, et al. Antithymocyte globulin and
cyclosporin in children with acquired aplastic anemia. Indian J Pediatr. 2008 Mar;75(3):229-33
Treatment Failure
20-40% fail to respond to combined IST
Give second course – 77% respond
Patients failing to respond to 2 courses- unlikely to respond to third course
Give trial of androgens, eltromopag, g-csf
Role of steroidsHigh dose steroids not
recommended as 1st lineMethylprednisolone in the dose
2mg/kg/day as 0.5mg/kg/dose 6hrly
Prednisone taper following 8 day course of IV methylprednisolone over total of 15 days
Role of G-CSFG-CSFincreases neutrophil recoveryno increase in trilineage responseFlu like symptomsInc risk of clonal evolutionSeiji Kojima, et al concluded, G-CSF
therapy did not modify long-term hematopoietic recovery and survival in patients with severe and very severe AA
Role of eltromopagThrombopoeitin mimeticIdeally should be ineffective- already high
levelsIn contrast – 40% responded
(bilineage/trilineage)Inc Hb n BM cellularity transfusionsSE – risk of progression to MDS
Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol
Educ Program. 2013;2013:76-81
Role of cyclophosphamideUsed in pastEfficacy similar to horse ATGFewer relapse rateBut excessively toxic and inc risk
of fungal infectionsNot recommended anymore
Tisdale JF, et al.High-dose cyclophosphamide in severe aplastic
anaemia: a randomised trial. Lancet 2000;356(9241):1554-1559
Haematopoetic stem cell transplantation<20yrs n HLA matched donors 5yr survival rate 88-97%Matched unrelated donors, unrelated cord blood
survival rate <50%Gupta V, et al.Impact of age on outcomes
after bone marrow transplantation for acquired aplastic anemia using HLA
matched sibling donors.Hematologica. 2010;95(12):2119-2125
StepsHLA matchingPreoperative conditioning regimen
ATG + cyclophosphamide + cyclosporine
Transplantation
ComplicationsGVHDSecondary solid tumorsEffect on growth n developmentEffect on endocrine functionEffect on gonadal functionPreexisting anti HLA antibodies affect
outcome Zhu H, et al. Pre-existing anti-HLA
antibodies negatively impact survival ofpediatric aplastic anemia patients undergoing
HSCT. Clin Transplant. 2014 Aug 14
Keys to a successful transplant
Level of HLA matchingGood conditioning regimen exposure to blood productsUse of leukocyte free productsFludarabine conditioningUse of BM stem cell plants rather than
peripheral blood
Schrezenmeier H, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells
than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired
aplastic ane- mia. Blood. 2007;110(4):1397-1400.
Fanconi’s anemiaMC inherited causeGenes – FANCA, B, C, D99% AR, except FANCB – XLRFaulty DNA damaged response &
genomic instability
Hematopoeitic failure & cancer predisposition
Median age – 7yrsUsual sequence – thrombocytopenia
granulocytopenia
Macrocytic anemiaFrequently terminates into MDS / AMLDiagnosis- chromosome breakage analysisBM – hypocellular & fatty replacement
with degree of peripheral pancytopenia
Congenital anomaliesHyperpigmentation of skinCafe au lait spotsShort statureSkeletal abnormalitiesMale hypogonadismAbnormalities of eyes n earsDevelopmental delayRenal n cardiac anomalies
complicationsRisk of hematological malignancies – 33%
Risk of non-hematological malignancies – 28%
Limb n skeletal abnormalities – 70%
ManagementMild to moderate cytopenia – monitor
counts every 3-4mths n BMA yearlyModerate to severe cytopenia Androgen therapy – oral
oxymetholone, 2-5mg/kg/day, slowly tapered
Response seen in 50% within 1-2mths
Prednisolone 1mg/kg added from day2
G-CSF daily/ every 2days with erythropoeitin given sc or iv 3times/week
Increase ANC, platelets & Hb levels
Allogenic HSCT – only curative treatment
in children < 10yrs, survival rate > 80%
Gene therapy – experimental
THANK YOU